Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Purple Biotech ( (PPBT) ) has shared an announcement.
On March 17, 2026, Purple Biotech announced it had regained compliance with Nasdaq’s minimum bid price requirement for continued listing on the Nasdaq Capital Market. The company satisfied Nasdaq Listing Rule 5550(a)(2) after its American Depositary Shares closed at or above $1.00 for at least 10 consecutive business days, a milestone reached on March 13, 2026, which removes an immediate delisting risk and supports continued access to U.S. capital markets.
The restored compliance strengthens Purple Biotech’s financial market positioning as it advances its oncology pipeline, including the CAPTN-3 immunotherapy platform and clinical-stage assets CM24 and NT219. For investors and partners, the confirmation from Nasdaq’s Listing Qualifications Department secures the company’s U.S. listing status at a time when it is preparing key programs for further clinical and partnering milestones.
The most recent analyst rating on (PPBT) stock is a Sell with a $4.00 price target. To see the full list of analyst forecasts on Purple Biotech stock, see the PPBT Stock Forecast page.
Spark’s Take on PPBT Stock
According to Spark, TipRanks’ AI Analyst, PPBT is a Neutral.
The score is held down primarily by weak financial performance (minimal revenue, widening losses, and continued cash burn alongside a shrinking equity base). Technicals are also bearish with negative momentum and price below key moving averages, only partially offset by oversold signals. Valuation contributes little support due to unprofitability and no dividend data.
To see Spark’s full report on PPBT stock, click here.
More about Purple Biotech
Purple Biotech Ltd. is a clinical-stage biotechnology company headquartered in Rehovot, Israel, focused on developing a next-generation immunotherapy platform to treat cancer. Its lead CAPTN-3 platform comprises masked tri-specific antibodies that target tumors while engaging both T cells and NK cells, with lead candidate IM1240 advancing toward the clinic and IM1305 in preclinical development, alongside additional clinical-stage assets CM24 and NT219 awaiting further partnering or investment.
Average Trading Volume: 13,558
Technical Sentiment Signal: Strong Sell
Current Market Cap: $5.95M
Learn more about PPBT stock on TipRanks’ Stock Analysis page.